期刊文献+

树突状细胞激活效应细胞的最佳效靶比及其体外杀伤活性的研究 被引量:1

STUDY ON THE OPTIMAL EFFICIENT RATIO ON TARGET CELLS AND THE ANTITUMOR ACTIVITY OF EFFECT CELLS STIMULATED BY DENDRITIC CELLS IN VITRO
下载PDF
导出
摘要 目的:探讨树突状细胞(DC)激活肿瘤浸润淋巴细胞(TIL)和小鼠脾淋巴细胞(小鼠脾LC)的最佳效靶比并观察被有效激活的TIL和小鼠脾LC等对小鼠H22肝癌细胞的体外杀伤作用。方法:从荷瘤小鼠四肢长骨提取DC,联合应用GM-CSF、IL-4和小鼠H22肝癌细胞全细胞性抗原致敏DC,然后依据不同的激活效靶比用致敏DC体外激活TIL、小鼠脾LC,分别检测、比较被不同程度激活的TIL、小鼠脾LC以及未激活的小鼠脾LC、未激活的TIL对小鼠H22肝癌细胞的杀伤活性。结果:①当DC∶靶细胞(E/T)为1∶400和1∶200时,所激活的TIL或小鼠脾LC的杀伤活性较弱;当E/T为1∶100时,杀伤活性有较明显的提高,与前两者比较,差异有统计学意义(P<0.05);当E/T=1∶50时,杀伤活性增加,与前三者比较差异均有统计学意义(P<0.01或P<0.05);而当E/T=1∶25、1∶12.5和1∶6.25时,杀伤活性与E/T=1∶50时比较无明显变化(P>0.05);②当E/T=1∶50时,未经DC激活的小鼠脾LC(A组)杀伤率为(9.73±1.40)%,未经DC激活的TIL(B组)和DC激活的小鼠脾LC(C组)杀伤率分别为(50.91±2.36)%和(49.70±2.70)%,DC激活的TIL(D组)的杀伤率为(73.49±2.46)%。A组与其他组分别比较,差异均有统计学意义(P<0.01);B组和C组比较差异无统计学意义(P>0.05);D组与其他各组分别比较,差异均有统计学意义(P<0.01)。结论:①当E/T=1∶50时,DC能很好的发挥抗原提呈作用,使小鼠脾LC和TIL得以充分激活;②充分激活的小鼠脾LC或TIL对小鼠H22肝癌细胞的体外杀伤活性较未激活的小鼠脾LC或未激活的TIL均具有明显的提高,尤以激活的TIL的杀伤活性最强。 Abstract Objective: To investigate the optimal efficient ratio of efficacy to target (E/T) and the antitumor activity of tumor-infiltrating lymphocytes(TILs) and the mouse's splenocyte lymphocytes stimulated by dendritic cells(DCs) on H22 cells in vitro. Methods: DCs were isolated from mouse bone marrow and stimulated by granuloeyte/ macrophage colony stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor cellular antigen. Then TILs and the mouse's splenocyte lymphocytes were stimulated by the activation DCs under different E/T conditions, and their anti-tumor activity on H22 cells in vitro were observed respectively. Results:(1)At E/T of 1 : 400 and 1 : 200 respectively, the anti-tumor activity of TILs or the mouse's splenocyte lymphocytes stimulated by DCs were low respectively; at E/T of 1 : 100, the antitumor activity increased, and the difference was significant as compared with those at E/T of 1 : 400 and 1 : 200 respectively ( P 〈0.05); at E/T of 1 : 50, the anti-tumor activity increased remarkably,and there was significant difference as compared with those at E/T of 1 : 400 , 1 : 200 and 1 : 100 respectively ( P〈 0. 01 or P 〈0.05) ; but at E/T of 1 : 25, 1 : 12.5 and 1 : 6.25 respectively, the anti-tumor activity almost had no change as compared with that at E/T of 1 : 50( P 〉0.05). (2)at E/T of 1 : 50, the anti-tumor activity of the mouse's splenocyte lymphocytes not stimulated by DCs(group A) was(9. 73±1.40)%, while the antitumor activity of the TILs not stimulated by DCs (group B) and the mouse's splenocyte lymphocytes stimulated by DCs (group C) were (50.91 ± 2.36) % and (49.70±2.70) % respectively. The antitumor activity of the TILs stimulated by DCs (group D) was(73.49± 2.46)%. the anti-tumor activity o{ group A as compared with those of other three groups respectively had a significant difference ( P 〈0.01),there wasn't a significant difference between the anti-tumor activity of group B and that of group C ( P 0. 05),the anti-tumor activity of group D as compared with the others respectively had a significant difference (P d0. 01). Conelusion:(1)At E/T of 1 : 50,TILs and the mouse's splenocyte lymphocytes can be stimulated efficiently by DCs. (2)the anti-tumor activity of TILs and the mouse's splenocyte lymphocytes stimulated efficiently by DCs on H22 cells were significantly higher than those of TILs and the mouse's splenocyte lymphocytes not stimulated by DCs respectively, and especially for TILs stimulated efficiently by DCs, the anti-tumor activity was highest.
出处 《广西医科大学学报》 CAS 北大核心 2007年第4期493-496,共4页 Journal of Guangxi Medical University
基金 广西科学研究与技术开发计划攻关项目(No.桂科攻0143052)
关键词 树突状细胞 肿瘤浸润淋巴细胞 效靶比 杀伤活性 dendritic cell tumor-infiltrating lymphocyte stimulate anti-tumor activity
  • 相关文献

参考文献9

  • 1Rosenberg SA,Spiess P,Diane S,et al.A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.Science,1986,233 (4770):1318.
  • 2Gilboa E,Nair SK,Lyerly HK.Immunotherapy of Cancer with dendritic-cell-based vaccines.Cancer Immunother,1998,46(2):82.
  • 3李挺,刘剑勇,刘剑仑,韦长元,杨南武,张力图.肝癌疫苗激活的肿瘤浸润性淋巴细胞治疗原发性肝癌的研究[J].中华普通外科杂志,2002,17(4):202-203. 被引量:3
  • 4Stift A,Friedl P,Dubsky T,et al.Dendritic cell-based vaccination in solid cancer.J Clin Oncol,2003,21 (1):135-142.
  • 5Inaba K,Inaba M,Romani N,et al.Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colonystimulating factor.J Exp Med,1992,176(6):1693-1702.
  • 6Monzavi KB,Kieber ET.Current concepts in cancer vaccine strategies.Biotechniques,2001,30:170-172.
  • 7Bellone M,Cantarella D,Castiglioni P,et al.Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.J Immunol,2000,165 (5):2651 -2656.
  • 8曹雪涛.树突状细胞的基础与临床研究新进展[J].中国免疫学杂志,1998,14(3):167-168. 被引量:117
  • 9Sallusto F,Lanzavecchia A.Efficient presentation of soluble antigen by culture human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 down-reguleted by tumor necrosis factor-α.J Exp Med,1994,179(4):1109.

二级参考文献17

共引文献117

同被引文献28

  • 1姚俊,杨欢,高宏君.热休克蛋白在肿瘤免疫中的研究进展[J].中国医疗前沿,2008,3(15):34-36. 被引量:1
  • 2鞠晓红,赵珍谊,方芳,马爱新.人脐血贴壁层细胞对脐血造血细胞体外扩增的作用[J].中国组织工程研究与临床康复,2007,11(7):1280-1281. 被引量:4
  • 3Amy M.Hicks,Gregory Riedlinger,Mark C.Willingham,et al.Transferable anticancer innate immunity in spontaneous regression complete resistance mice.PNAS.2006;103(20):7753-7758.
  • 4Gattinoni L,Powell DJ Tr,Rosenberg SA,et al.Adoptive immunotherapy for cancer:building on success.Nat Rev Immunol.2006;6(5):383-393.
  • 5Williams LM,Rudensky AY.Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.Nat Immunol.2007;8(3):277-284.
  • 6Tesniere A,Panaretakis T,Kepp O,Apetoh L,Ghiringhelli F,Zitvogel L,Kroemer G.Molecular characteristics of immunogenic cancer cell death.Cell Death Differ.《 2008;15(1):3-12.
  • 7Rescigno M,Avogadri F,Curigliano G.Challenges and prospects of immunotherapy as cancer treatment.Biochim Biophys Aeta.2007;1776(1):108-123.
  • 8McKee MD,Roszkowski JJ,Nishimura MI.T cell avidity and tumor recognition:implications and therapeutic strategies.J Transl Med.2005;3:35.
  • 9June CH.Adoptive T cell therapy for cancer in the clinic.J Clin Invest.2007;117(6):1466-1476.
  • 10June CH.Principles of adoptive T cell cancer therapy.J Clln In vest.2007;117(5):1204-1212.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部